New health technologies need new approaches
Dr Sam Roberts has been outlining the changes underway at NICE to meet the challenges of a rapidly evolving health technology sector and patient expectations
Dr Sam Roberts has been outlining the changes underway at NICE to meet the challenges of a rapidly evolving health technology sector and patient expectations
A patient decision aid on medicines associated with dependence or withdrawal symptoms has been published
Delivering fewer radiotherapy sessions over a shorter period of time, first introduced during COVID, benefits patients and the system long-term
NICE has approved mavacamten, the first treatment that specifically targets a heart condition called obstructive hypertrophic cardiomyopathy (HCM). It means around 7,000 people will now be able to access the treatment on the NHS.
NICE has for the first time recommended an oral treatment for preventing migraines.
NICE’s priority is to get the best care to patients fast while ensuring value for the taxpayer.
Page 21 of 39